Vital Farms Q3 2026: Revenue declines 8.4% YoY but improves sequentially

What happened

Vital Farms reported third quarter 2026 net revenue of $182.2 million, a decrease of 8.4% year over year and a sequential increase of 9.7% from the second quarter. The year-over-year decline suggests the company continues to face challenges from the ERP transition and order-pattern disruptions identified in the prior year, though the sequential growth indicates some normalization. The company had guided to FY2026 net revenue of $930 million to $950 million, but the Q3 run-rate of $182.2 million annualizes to roughly $729 million, implying the company is likely to fall far short of that target and may have already reduced its outlook. The master report's base case assumed normalized ordering and revenue recovery, but this print suggests recovery is slower than expected and the bear case is becoming more probable. This result is a negative catalyst that increases the likelihood of a guidance cut and reinforces the Wait rating.

Implication

The Q3 2026 revenue miss relative to initial guidance signals the ERP issues may have longer-lasting impact than anticipated, undermining the FY2026 growth story and pushing the company closer to the bear case of $21 implied value. Investors should focus on whether management cuts or withdraws the FY2026 outlook and whether the material weakness in revenue-process controls is remediated, as these are key thesis breakers. Until there is concrete evidence of normalized order patterns and revenue re-acceleration, the stock is likely to remain under pressure and the Wait rating should be maintained or downgraded. Only a clear recovery in Q4 and a credible path to 2027 targets would warrant reconsideration. The balance sheet remains net cash, but the operating underperformance reduces the margin of safety.

Thesis delta

The investment thesis shifts from cautiously waiting for normalization to acknowledging that recovery is slower than expected and that the bear case is becoming more likely. The Q3 2026 revenue decline of 8.4% YoY despite sequential growth indicates the ERP disruption may have persistent effects on order patterns and revenue, undermining the initial FY2026 guidance of $930-$950 million. Unless management provides a credible explanation and a strong Q4, the stock may be overvalued at current levels and the Wait rating should be maintained with a downward bias. The governance overhang from the unremediated material weakness further increases risk.